What Makes Vaxcyte (PCVX) So Attractive

Vaxcyte Inc. (NASDAQ:PCVX) is one of the most promising mid-cap healthcare stocks under $50.

On December 9, BTIG analyst Thomas Shrader reiterated his bullish view of Vaxcyte Inc. (NASDAQ:PCVX). He assigned a Buy rating to the stock with a target price of $85. This results in an upside of over 83% from the current level.

Sharder mentioned the positive results from Phase 2 trials for the VAX-31 vaccine, which will prove to be a building block for the critical Phase 3 trials. The upcoming trial’s robust design involves a stringent success criterion involving a noninferiority margin for immunogenicity. This could ensure that VAX-31 would turn out to be a more effective cure for adult pneumococcal conditions.

Sharder also highlighted the target market for VAX-31, which ranges from ages 50 to 65 and offers potential for strong market adoption. The analyst views all these factors to place Vaxcyte Inc. (NASDAQ:PCVX) in a strong competitive position.

Even the consensus ratings also indicate analysts’ optimism about Vaxcyte Inc. (NASDAQ:PCVX). At the close of play on December 19, all 7 ratings assigned to the stock were Buy, with consensus forecasts showing a median 1-year price target of $100.80 per share. This offers investors a whopping 117.2% upside from the current trading levels.

Vaxcyte Inc. (NASDAQ:PCVX) is a company involved in the development of next-generation vaccines that offer protection against threatening bacterial diseases. Currently a clinical-stage company, Vaxcyte Inc. (NASDAQ:PCVX) deploys innovative synthetic methods and advanced chemistry to produce complex high-fidelity vaccines that contain enhanced immunological benefits.

While we acknowledge the risk and potential of PCVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PCVX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.